Rob Kania

Rob Kania

Company: Kinnate

Job title: Senior Vice President of Drug Discovery

Seminars:

Progress in Newly Diagnosed Actionable Mutations 9:00 am

• Rationale & updates for novel TKIs • Discussing the safety and efficacy of novel TKIs that target the eight molecular subtypes/currently actionable alterations • Latest data & future directionsRead more

day: Day One

Breakfast Panel: Bridging the TKI vs. Immunotherapy Conversations in NSCLC 9:00 am

Discussing stage of cancer, combinations, and order of treatment rationale for the well-validated immunotherapies and TKIs in early lines Exploring shifts of focus between the immune system of the patient (immunotherapies) and the biology of the tumor (tyrosine kinase inhibitors) How can we combine insights from both immune system markers and tumor markers, to be…Read more

day: Day Two

Progress in Newly Diagnosed Actionable Mutations 9:00 am

Rationale & updates for novel TKIs Discussing the safety and efficacy of novel TKIs that target the eight molecular subtypes/currently actionable alterations Latest data & future directionsRead more

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.